keyword
MENU ▼
Read by QxMD icon Read
search

Virus C and liver transplantation

keyword
https://www.readbyqxmd.com/read/29341040/risk-factors-for-allograft-failure-in-liver-transplant-recipients
#1
Anna Huesing-Kabar, Christina Zu Dohna, Hauke Heinzow, Vito Rosario Cicinnati, Susanne Beckebaum, Martina Schmidt, Hans Ulrich Gerth, Michele Pohlen, Christian Wilms, Daniel Palmes, Hartmut Hans-Jürgen Schmidt, Iyad Kabar
BACKGROUND:  With regard to quality of life and organ shortage, follow-up after liver transplantation (LT) should consider risk factors for allograft failure in order to avoid the need for re-LT and to improve the long-term outcome of recipients. Therefore, the aim of this study was to explore potential risk factors for allograft failure after LT. MATERIAL AND METHODS:  A total of 489 consecutive LT recipients who received follow-up care at the University Hospital of Muenster were included in this study...
January 16, 2018: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/29329373/co-existing-hepatitis-c-and-alcoholic-liver-disease-a-diminishing-indication-for-liver-transplantation
#2
Amanda Wieland, Gregory T Everson
Aims: To provide an overview of published literature on the interaction of alcohol and hepatitis C virus (HCV) in the accelerated progression of liver disease to cirrhosis as relates to decision-making for the management of the liver transplant candidate and recipient. Methods: General PubMed search was employed along with expert input to identify the relevant articles on the topic. The authors also utilized both backward and forward citation review of the relevant articles and reviews to identify articles on identified topic...
January 10, 2018: Alcohol and Alcoholism: International Journal of the Medical Council on Alcoholism
https://www.readbyqxmd.com/read/29328556/coronary-artery-disease-in-decompensated-patients-undergoing-liver-transplantation-evaluation
#3
Samarth S Patel, Eiman Nabi, Luis Guzman, Antonio Abbate, Chandra Bhati, Richard T Stravitz, Trevor Reichman, Scott C Matherly, Carolyn Driscoll, Hannah Lee, Velimir A Luketic, Richard K Sterling, Arun J Sanyal, Vaishali Patel, Marlon Levy, Mohammad Shadab Siddiqui
Coronary artery disease (CAD) is an important contributor to morbidity and mortality in patients undergoing liver transplantation (LT). However, the current literature is limited by sampling bias and non-definitive assessment of CAD. AIM: The current study examines the prevalence of CAD via per protocol coronary angiography and its relationship to etiology of liver disease in patients undergoing LT evaluation (LTE). METHODS: Data on 228 patients was prospectively collected who had coronary angiography as part of LTE between 2011-2014...
January 12, 2018: Liver Transplantation
https://www.readbyqxmd.com/read/29327821/chronic-kidney-disease-in-patients-with-chronic-hepatitis-c-virus-infection
#4
Omer Shahab, Pegah Golabi, Zobair M Younossi
Hepatitis C virus (HCV) infection affects many organs in the body, including the liver, kidneys, skin, joints and others. Although the hepatic manifestation of HCV has been widely studied, the extrahepatic manifestaions of HCV have not been fully appreciated. Studies have shown that patients with HCV have a higher risk of chronic kidney disease and end-stage renal disease, as well as poorer outcomes after kidney transplantation. Given these findings, it is important to screen HCV patients for presence of renal impairement in a timely manner...
January 10, 2018: Minerva Gastroenterologica e Dietologica
https://www.readbyqxmd.com/read/29325297/-sofosbuvir-combined-with-daclatasvir-in-treatment-of-a-patient-with-hepatitis-c-virus-infection-undergoing-liver-and-renal-transplantation-a-case-report
#5
X H Gao, X F Hao, P Jing, G H Xu
No abstract text is available yet for this article.
December 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29322398/hepatitis-c-virus-infection-and-development-of-type-2-diabetes-mellitus-systematic-review-and-meta-analysis-of-the-literature
#6
REVIEW
Silvia Fabiani, Poupak Fallahi, Silvia Martina Ferrari, Mario Miccoli, Alessandro Antonelli
Type 2 diabetes mellitus (T2DM) is an endocrine disorder encompassing multifactorial mechanisms, and chronic hepatitis C virus infection (CHC) is a multifaceted disorder, associated with extrahepatic manifestations, including endocrinological disorders. CHC and T2DM are associated, but the subject remains controversial. We performed a systematic review and meta-analysis evaluating such association, searching on PubMed until February 29, 2016. Inclusion criteria were: 1) presence of at least one internal control group age- and gender-matched (non-hepatopathic controls; and/or hepatopathic, not HCV-positive, controls); 2) sufficient data to calculate odds ratio and relative risk...
January 11, 2018: Reviews in Endocrine & Metabolic Disorders
https://www.readbyqxmd.com/read/29305405/real-world-treatment-of-hepatitis-c-with-second-generation-direct-acting-antivirals-initial-results-from-a-multicentre-canadian-retrospective-cohort-of-diverse-patients
#7
Alex I Aspinall, Abdel A Shaheen, Golasa S Kochaksaraei, Breean Haslam, Samuel S Lee, Gisela Macphail, Jeff Kapler, Oscar E Larios, Kelly W Burak, Mark G Swain, Meredith A Borman, Carla S Coffin
BACKGROUND: High hepatitis C cure rates have been observed in registration trials with second-generation direct-acting antivirals. Real-world data also indicate high sustained viral response (SVR) rates. Our objective was to determine real-world SVR rates for patients infected with hepatitis C virus (HCV) who were treated with second-generation direct-acting antivirals in the first 18 months of their availability in Canada. METHODS: Four centres in Calgary contributed their treatment data for a diverse patient population including those who had or had not undergone liver transplantation, those coinfected with HIV and vulnerable populations...
January 5, 2018: CMAJ Open
https://www.readbyqxmd.com/read/29299684/treatment-of-hepatitis-c-in-special-populations
#8
REVIEW
Goki Suda, Koji Ogawa, Kenichi Morikawa, Naoya Sakamoto
Hepatitis C virus (HCV) infection is one of the primary causes of liver cirrhosis and hepatocellular carcinoma. In hemodialysis patients, the rate of HCV infection is high and is moreover associated with a poor prognosis. In liver transplantation patients with HCV infection, recurrent HCV infection is universal, and re-infected HCV causes rapid progression of liver fibrosis and graft loss. Additionally, in patients with HCV and human immunodeficiency virus (HIV) co-infection, liver fibrosis progresses rapidly...
January 3, 2018: Journal of Gastroenterology
https://www.readbyqxmd.com/read/29279693/a-rare-case-of-classical-hodgkin-lymphoma-diagnosed-10-years-after-liver-transplant
#9
L Zhang, R Pereira Mestre, F Bihl, M Bühler, B Vannata, A Stathis
Posttransplant lymphoproliferative disorders (PTLD) represent a rare and potentially life-threatening complication after liver transplantation. Classical Hodgkin lymphoma (cHL), with an incidence of approximately 1.8-3.4% of all PTLD cases, represents a minority of PTLD, mainly presenting as a late transplant complication. The main risk factors for the development of PTLD are Epstein-Barr virus (EBV) infection and intensive immunosuppression. However, other risk factors like hepatitis C virus may, together with EBV infection, contribute to the development of PTLD...
September 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/29274178/assessing-uncertainty-in-the-burden-of-hepatitis-c-virus-comparison-of-estimated-disease-burden-and-treatment-costs-in-the-uk
#10
Finn Gubay, Roisin Staunton, Cornelia Metzig, Ibrahim Abubakar, Peter J White
Hepatitis C virus (HCV) is a major and growing public health concern. We need to know the expected health burden and treatment cost, and understand uncertainty in those estimates, to inform policy-making and future research. Two models that have been important in informing treatment guidelines and assessments of HCV burden were compared by simulating cohorts of individuals with chronic HCV infection initially aged 20, 35, and 50 years. One model predicts that health losses (measured in Quality-Adjusted Life-Years (QALYs)) and treatment costs decrease with increasing initial age of the patients, whilst the other model predicts that below 40 years, costs increase and QALY losses change little with age, and above 40 years they decline with increasing age...
December 23, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29259634/prevalence-of-hepatitis-c-infection-in-iranian-hemodialysis-patients-an-updated-systematic-review-and-meta-analysis
#11
REVIEW
Nahid Ramezan Ghorbani, Shirin Djalalinia, Mitra Modirian, Zahra Esmaeili Abdar, Morteza Mansourian, Armita Mahdavi Gorabi, Hamid Asayesh, Hossein Ansari, Mehrdad Kazemzadeh Atoofi, Ramin Tajbakhsh, Mehdi Noroozi, Saeid Safiri, Mostafa Qorbani
Background: Hepatitis C virus (HCV) is a major cause of liver disease and a potential cause of substantial morbidity and mortality. This study aims to provide a comprehensive evidence on HCV Infection in Iranian hemodialysis (HD) patients we conducted a systematic review. Materials and Methods: In this systematic review and meta-analysis, through a comprehensive search of literature until January of 2016, we estimated the pooled prevalence of hepatitis C infection in Iranian HD patients...
2017: Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences
https://www.readbyqxmd.com/read/29259601/preclinical-development-and-production-of-virus-like-particles-as-vaccine-candidates-for-hepatitis-c
#12
REVIEW
Makutiro Ghislain Masavuli, Danushka K Wijesundara, Joseph Torresi, Eric J Gowans, Branka Grubor-Bauk
Hepatitis C Virus (HCV) infects 2% of the world's population and is the leading cause of liver disease and liver transplantation. It poses a serious and growing worldwide public health problem that will only be partially addressed with the introduction of new antiviral therapies. However, these treatments will not prevent re-infection particularly in high risk populations. The introduction of a HCV vaccine has been predicted, using simulation models in a high risk population, to have a significant effect on reducing the incidence of HCV...
2017: Frontiers in Microbiology
https://www.readbyqxmd.com/read/29249127/liver-transplantation-for-non-alcoholic-fatty-liver-disease
#13
Giacomo Germani, Chiara Becchetti
Non-alcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of metabolic syndrome (MS) [1], and it is defined by the presence of steatosis in >5% of hepatocytes, according to histological analysis or detected by specific proton density fat fraction obtained MRI. The term NAFLD covers two pathologically distinct conditions: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), which can have similar clinical presentation, but with different prognosis. Both conditions can lastly lead to the development of cirrhosis...
December 15, 2017: Minerva Gastroenterologica e Dietologica
https://www.readbyqxmd.com/read/29238003/direct-acting-agents-for-hepatitis-c-virus-before-and-after-liver-transplantation
#14
Yasuhiko Sugawara, Taizo Hibi
Chronic hepatitis C virus (HCV) infection remains a widespread public health concern and many people are infected with HCV. HCV is one of the leading indications for liver transplantation. Direct-acting antiviral agents (DAAs) against HCV have changed the course of chronic HCV infection, however, making it a curable disease. DAA treatment may be initiated before or after liver transplantation. In the present review, we present the available data on DAA treatment of HCV in liver transplant recipients.
December 14, 2017: Bioscience Trends
https://www.readbyqxmd.com/read/29232254/orthotropic-live-transplantation-for-cirrhosis-from-hepatitis-c-virus-leads-to-correction-of-factor-ix-deficiency-allowing-for-ankle-arthroplasty-without-factor-replacement-in-a-patient-with-moderate-haemophilia-b
#15
Kumiko Ono, Jun Hirose, Song H Chang, Minoru Kubota, Junya Kinkawa, Megumi Noguchi, Hideyuki Takedani
: Liver transplantation is one of the treatments for haemophilic patients having severe liver cirrhosis who are infected with the hepatitis C virus. Patients with haemophilia can develop arthroplasty requiring surgical intervention, and the surgical outcomes of patients undergoing such procedures after liver transplant has not been reported. Treatment for arthropathy is important for improving the quality of life for patients who survive after liver transplantation. We report the first case of ankle arthroscopic arthrodesis in a patient with haemophilia B after undergoing living donor liver transplantation...
December 11, 2017: Blood Coagulation & Fibrinolysis: An International Journal in Haemostasis and Thrombosis
https://www.readbyqxmd.com/read/29226102/timing-of-hepatitis-c-virus-treatment-in-liver-transplant-candidates-in-the-era-of-direct-acting-antiviral-agents
#16
REVIEW
George Cholankeril, Mairin Joseph-Talreja, Brandon J Perumpail, Andy Liu, Eric R Yoo, Aijaz Ahmed, Aparna Goel
Chronic hepatitis C virus (HCV) infection remains the leading indication for liver transplantation (LT) in the United States. While most patients with chronic HCV infection remain asymptomatic, up to one-third develop progressive liver disease resulting in cirrhosis. LT is often the only curative treatment once significant hepatic decompensation develops. However, antiviral therapy for HCV infection has advanced markedly in the past 5 years with the discovery and approval of direct-acting antiviral agents. These new regimens are well tolerated, of short duration and highly effective, unlike the traditional treatment with pegylated-interferon and ribavirin...
December 28, 2017: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/29222916/transplanting-hcv-positive-livers-into-hcv-negative-patients-with-preemptive-antiviral-treatment-a-modeling-study
#17
Jagpreet Chhatwal, Sumeyye Samur, Emily D Bethea, Turgay Ayer, Fasiha Kanwal, Chin Hur, Mark S Roberts, Norah Terrault, Raymond T Chung
Under current guidelines hepatitis C virus (HCV)-positive livers are not transplanted into HCV-negative recipients because of adverse post-transplant outcomes associated with allograft HCV infection. However, HCV can now be cured post liver transplant (LT) using direct-acting antivirals (DAAs) with >90% success; therefore, HCV-negative patients on the liver transplant (LT) waiting list may benefit from accepting HCV-positive organs with preemptive treatment. Our objective was to evaluate if and in which HCV-negative patients the potential benefit of accepting an HCV-positive (i...
December 9, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29219790/hepatitis-c-virus-infection-in-kidney-transplant-patients-current-treatment-options
#18
Pavlina Dzekova-Vidimliski, Aleksandar Sikole
Hepatitis C virus infection is highly prevalent among kidney transplant recipients, occurring consequently to their previous treatment with hemodialysis. Hepatitis C virus infection has been associated with lower graft and patient survival compared with that shown in patients without infection. The lower survival has been associated with the posttransplant progression of liver disease and increased risk for development of extrahepatic complications. The choice of immunosuppressive drugs could significantly affect the course of the infection with an accelerated viral replication after kidney transplant...
December 2017: Experimental and Clinical Transplantation
https://www.readbyqxmd.com/read/29205441/hepatitis-c-transmission-from-seropositive-non-viremic-donors-to-non-hepatitis-c-liver-transplant-recipients
#19
Khurram Bari, Keith Luckett, Tiffany Kaiser, Tayyab Diwan, Madison Cuffy, Michael Schoech, Kamran Safdar, Jason T Blackard, Senu Apewokin, Flavio Paterno, Kenneth E Sherman, Stephen D Zucker, Nadeem Anwar, Shimul A Shah
Breakthroughs in Hepatitis C virus (HCV) treatment and rising rates of intravenous drug use have led to an increase in the number of organ donors that are HCV antibody positive but serum nucleic acid test (NAT) negative. The risk of HCV transmission from the liver grafts of these donors to recipients is unknown. To estimate the incidence of HCV transmission, we prospectively followed 26 consecutive HCV antibody (n=25) or NAT (n =1) negative transplant recipients who received a liver graft from donors that were HCV antibody positive but serum NAT negative between March 2016 and March 2017...
December 2, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29205405/interferon-free-therapy-of-chronic-hepatitis-c-with-direct-acting-antivirals-does-not-change-the-short-term-risk-for-de-novo-hepatocellular-carcinoma-in-patients-with-liver-cirrhosis
#20
F Mettke, B Schlevogt, K Deterding, A Wranke, A Smith, K Port, M P Manns, A Vogel, M Cornberg, H Wedemeyer
BACKGROUND: Hepatitis C virus (HCV) clearance with IFN-based therapies reduces the incidence of hepatocellular carcinoma (HCC). There has been some debate if IFN-free therapy with direct-acting antivirals alters the risk for HCC. AIM: To investigate the HCC incidence in cirrhotic HCV patients who cleared HCV with direct-acting antivirals vs untreated controls. METHODS: We prospectively monitored 373 patients with chronic hepatitis C who received IFN-free therapies with direct-acting antiviral after January 2014...
December 4, 2017: Alimentary Pharmacology & Therapeutics
keyword
keyword
112674
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"